Research Analysts Issue Forecasts for Catalent Inc’s FY2018 Earnings (CTLT)

Catalent Inc (NYSE:CTLT) – Equities researchers at William Blair increased their FY2018 earnings estimates for Catalent in a research report issued to clients and investors on Wednesday, Zacks Investment Research reports. William Blair analyst J. Kreger now forecasts that the company will post earnings of $1.52 per share for the year, up from their prior forecast of $1.43. William Blair also issued estimates for Catalent’s Q4 2018 earnings at $0.63 EPS, Q2 2019 earnings at $0.38 EPS, Q3 2019 earnings at $0.45 EPS, Q4 2019 earnings at $0.67 EPS and FY2019 earnings at $1.76 EPS.

A number of other research firms have also recently commented on CTLT. BidaskClub cut shares of Catalent from a “buy” rating to a “hold” rating in a report on Tuesday, November 14th. First Analysis began coverage on shares of Catalent in a research note on Friday, January 5th. They issued an “equal weight” rating for the company. Zacks Investment Research raised shares of Catalent from a “hold” rating to a “strong-buy” rating and set a $49.00 price objective for the company in a research note on Thursday, October 26th. ValuEngine lowered shares of Catalent from a “buy” rating to a “hold” rating in a research note on Monday, October 2nd. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Catalent in a research note on Monday, October 23rd. Six analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $44.44.

Catalent (NYSE:CTLT) opened at $42.94 on Friday. The company has a quick ratio of 2.49, a current ratio of 2.91 and a debt-to-equity ratio of 2.01. The company has a market cap of $5,704.96, a PE ratio of 49.36, a PEG ratio of 2.73 and a beta of 1.41. Catalent has a 1-year low of $25.72 and a 1-year high of $43.42.

Catalent (NYSE:CTLT) last posted its quarterly earnings data on Monday, November 6th. The company reported $0.21 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.20 by $0.01. The business had revenue of $543.90 million for the quarter, compared to analysts’ expectations of $490.75 million. Catalent had a net margin of 5.01% and a return on equity of 23.97%. The business’s revenue was up 23.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.16 earnings per share.

In related news, Director Uwe Roehrhoff acquired 7,500 shares of the business’s stock in a transaction dated Tuesday, November 21st. The shares were purchased at an average price of $39.22 per share, for a total transaction of $294,150.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider John R. Chiminski sold 181,458 shares of the company’s stock in a transaction dated Tuesday, December 12th. The shares were sold at an average price of $39.62, for a total transaction of $7,189,365.96. The disclosure for this sale can be found here. Corporate insiders own 1.70% of the company’s stock.

Large investors have recently modified their holdings of the stock. 361 Capital LLC increased its holdings in Catalent by 18.6% in the 3rd quarter. 361 Capital LLC now owns 70,022 shares of the company’s stock worth $2,795,000 after buying an additional 10,974 shares during the period. Schwab Charles Investment Management Inc. increased its holdings in Catalent by 25.2% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 1,046,417 shares of the company’s stock worth $41,773,000 after buying an additional 210,296 shares during the period. Stevens Capital Management LP acquired a new position in Catalent in the 3rd quarter worth approximately $2,475,000. Sei Investments Co. increased its holdings in Catalent by 119.1% in the 3rd quarter. Sei Investments Co. now owns 94,216 shares of the company’s stock worth $3,761,000 after buying an additional 51,212 shares during the period. Finally, Renaissance Technologies LLC acquired a new position in Catalent in the 2nd quarter worth approximately $23,092,000. Institutional investors own 99.37% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Research Analysts Issue Forecasts for Catalent Inc’s FY2018 Earnings (CTLT)” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another site, it was copied illegally and republished in violation of United States & international copyright laws. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/01/21/fy2018-earnings-estimate-for-catalent-inc-ctlt-issued-by-william-blair.html.

About Catalent

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.

Get a free copy of the Zacks research report on Catalent (CTLT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply